Virbac confirmed 2026 outlook: Virbac stock sits 13.48 percent below its yearly high

Published on 10/18/2026 at 12:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue rose 7.40 percent to EUR 768.00 million. For Virbac stock, sales are due on October 19, 2026 after a 5.50 to 7.50 percent outlook.

Virbac outlook and valuation

Virbac confirmed its upper-end 2026 outlook on September 17, 2026.
Bernstein raised its target from EUR 419.00 to EUR 426.00 on September 21, 2026.
Virbac's market capitalization was EUR 2.8 billion on October 16, 2026, with a EUR 297.00 to EUR 389.50 range.

Geometrisches Bauhaus-Plakat mit dem Schriftzug PHARMA in kräftigen Farben — Bauhaus-Poster mit geometrischen Formen und Sektortext symbolisiert Virbac S.A., FR0000031577, Veterinärpharma-Industrie grafisch, Illustration mit AI erstellt.

Virbac (ISIN FR0000031577) confirmed its 2026 revenue outlook at the upper end of its 5.50 to 7.50 percent growth range on September 17, 2026, according to PR Newswire. The company is due to publish third-quarter sales on October 19, 2026, according to its investor calendar.

Revenue growth sets the tone

Virbac reported first-half 2026 revenue of EUR 768.00 million, up 7.40 percent at constant exchange rates and scope. The adjusted EBIT margin reached 18.80 percent, while consolidated net income rose 5.90 percent to EUR 87.10 million, according to PR Newswire. Companion-animal revenue increased 10.00 percent and farm-animal revenue grew 6.70 percent during the first half of 2026.

Three dates shape the year

On July 20, 2026, Virbac published second-quarter sales after reporting a first-half revenue base of EUR 768.00 million. On September 17, 2026, the company released its interim results and confirmed the 5.50 to 7.50 percent 2026 growth range. On October 6, 2026, Virbac marked 30 years of activity in Thailand, according to its investor page.

What does the analyst target imply?

Bernstein upgraded Virbac from Market-Perform to Outperform and lifted its target from EUR 419.00 to EUR 426.00 on September 21, 2026, as Investing.com reported. The new target lies 26.41 percent above the EUR 337.00 last price cited below. The coming sales release will provide the next quantified check on whether the first-half pace supports the upper end of the annual range.

Valuation sets the market frame

Virbac was last at EUR 337.00 on Euronext Paris on October 16, 2026 at 5:35 p.m. CEST. The same market snapshot showed a market capitalization of EUR 2.8 billion and a 52-week range of EUR 297.00 to EUR 389.50.